Heather L. Van Epps, PhD

Despite the lack of data to justify them, periodic surveillance PET scans during remission are performed frequently.

For patients with B-cell lymphomas, new treatments are providing more options.

Researchers need to learn more about the biology of liver cancer to develop better treatments.

Refined treatments and targeted drugs signal slow yet significant progress for liver cancer.

One alternative to targeting specific tumor-associated proteins is to entice the patient’s immune system to attack the tumor directly.

Focusing on screening and genetic clues, progress in lung cancer shifts forward.

Understanding the molecular makeup of triple-negative breast cancer reveals new therapeutic targets.

With more knowledge, triple-negative breast cancer doesn't seem so scary.

New treatments for multiple myeloma target the disease in different ways.

Sarcoma is more common in children and young adults.

Soft tissue sarcoma has benefited from research in other cancers.

Patients whose breast cancers are estrogen-positive have a wide variety of treatments available.

Neoadjuvant breast cancer therapy may be beneficial.

Some drugs used to treat cancer can trigger physiological responses that manifest in feelings of anger.

Coping with anger during cancer can be difficult.

New treatments for bladder cancer may be nearing the finish line.

Advocating for yourself.

The latest advancements in the treatment of Hodgkin lymphoma.

Although called a "good" cancer, Hodgkin lymphoma isn't always curable.

Half of adult patients diagnosed with non-Hodgkin lymphoma are over age 60--oncologists must take into account age and associated complications.

Predicting drug response in colorectal cancer.

KRAS gene mutations are detected in various cancers, including colorectal.

Issues after surgery can be taxing for patient and caregiver.

Exposing the ethical dilemmas of clinical trials reveals a balance between researchers, drug companies, and patients.

Data collection doesn’t end when a clinical trial ends, as rare or long-term side effects of a new drug or treatment may take years to emerge.

In an aging population, cancer is rarely a solo act.